HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
about
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemiaEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.New advances in genitourinary cancer: evidence gathered in 2014.Potential therapeutic effects of mTOR inhibition in atherosclerosis.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo.Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro.HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
P2860
Q26778780-9050C6E3-969C-4A58-B4E3-D63F95B61A85Q30313117-A9212963-0EA5-4B37-BB86-7CC912BEBDC9Q35691776-25BCE294-14E6-446A-B120-1C00DD56C3BAQ37709114-8DD825C2-761F-4A9C-94FA-3917EC2B2420Q38557894-08E32F2E-A6FF-4032-A504-DF35D529C3E5Q38628797-FBD1E524-5DC0-4BA7-90F5-4193204A4434Q38947405-F968C76E-38C1-429C-B87F-E3DE84A45A2FQ39379576-586C3156-AE71-486B-BE00-DBB88709DAB5Q41194522-958BC304-49C4-4BCE-8595-E16A5A1E91CBQ41837321-3B62C169-4E7C-4E14-9C7A-537BC0CEE2C9Q47100939-F9D326EE-49D8-4063-8E33-A47A422DAC3CQ48123819-B287E617-D177-4838-A6FC-34384304723DQ48528146-7630A5EC-9ACF-49F2-A5C8-9E45CF9554C2Q49849134-FCADEE15-83E3-407F-BA7B-D6BAE0B81DC1Q50682953-95FF4E38-16B0-41CE-9054-6D17B94A947DQ55318529-36F08F40-F075-47FA-BEF7-E797676D2CC9Q58773654-0E90F4A4-133C-4439-BE0E-CA614C0CA829
P2860
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
HDAC-inhibition counteracts ev ...... diminishing cdk2 and cyclin A.
@en
type
label
HDAC-inhibition counteracts ev ...... diminishing cdk2 and cyclin A.
@en
prefLabel
HDAC-inhibition counteracts ev ...... diminishing cdk2 and cyclin A.
@en
P2093
P2860
P356
P1433
P1476
HDAC-inhibition counteracts ev ...... diminishing cdk2 and cyclin A.
@en
P2093
Axel Haferkamp
Eva Juengel
Georg Bartsch
Igor Tsaur
Isabella Werner
Iyad Natsheh
Jasmina Makarevi
Karen Nelson
Michael Reiter
P2860
P2888
P356
10.1186/1476-4598-13-152
P577
2014-06-16T00:00:00Z
P5875
P6179
1043418275